<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[americans with disabilities act and fda Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/americans+with+disabilities+act+and+fda.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to americans with disabilities act and fda]]></description>
	<s:counts start="0" returned="3" found="3" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Statement by ADA President on Court's Refusal to Second-Guess the Food and Drug Administration's Position on Dental Amalgam]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5554/is_200704/ai_n21895863]]></link>
		<description><![CDATA[To: MEDICAL EDITORSTo: MEDICAL EDITORS]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 16 Apr 2007 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/americans+with+disabilities+act.html"><![CDATA[Americans with Disabilities Act]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[ADA Welcomes Additional Scientific Review of Dental Filling Safety]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5554/is_200609/ai_n21880420]]></link>
		<description><![CDATA[CHICAGO, Sept. 7 /U.S. Newswire/ -- The American Dental Association ADA welcomes the call by a U.S. Food and Drug Administration FDA panel for additional review of scientific studies on the safety of dental amalgam fillings. CHICAGO, Sept. 7 /U.S. Newswire/ -- The American Dental Association ADA welcomes the call...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 07 Sep 2006 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/americans+with+disabilities+act.html"><![CDATA[Americans with Disabilities Act]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Ligand Updates Naveglitazar Development Plan Following Positive Phase II Data Presentation at ADA and New FDA Divisional Guidance for PPAR Drug Development]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2004_July_8/ai_n6099779]]></link>
		<description><![CDATA[SAN DIEGO -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) commented on the positive Phase II data on naveglitazar (LY818) presented at the annual meeting of the American Diabetes Association ADA, and noted the new FDA Divisional guidance for the PPAR class of compounds. The new guidance will delay initiation of all...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 08 Jul 2004 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/americans+with+disabilities+act.html"><![CDATA[Americans with Disabilities Act]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
</channel>
</rss>
